Edgewise Therapeutics, Inc. (EWTX)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $4.98B
- P/E ratio
- —
- EPS
- —
- Volume
- 605,905
- 52-week high
- —
- 52-week low
- —
- Open
- $40.00
- Day high
- $40.68
- Day low
- $38.75
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$167.8M | -$1.63 |
| 2024 | — | -$133.81M | -$1.45 |
| 2023 | — | -$100.16M | -$1.57 |
| 2022 | — | -$67.64M | -$1.26 |
| 2021 | — | -$42.81M | -$1.14 |
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
- CEO
- Kevin Koch
- Employees
- 154
- Country
- US
- IPO date
- Mar 26, 2021
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Edgewise Therapeutics, Inc.'s stock price today?
- EWTX is trading at $38.81 as of Jul 20, 2026.
- What is Edgewise Therapeutics, Inc.'s market cap?
- Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of $4.98B.
- Does Edgewise Therapeutics, Inc. pay a dividend?
- Edgewise Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Edgewise Therapeutics, Inc. in?
- Edgewise Therapeutics, Inc. operates in the Healthcare sector.